Addex Therapeutics Reports Significant FY2025 Net Loss of CHF 6.7M; Cash Dwindles to CHF 1.6M
ADXN sits 31% above its 52-week low of $5.41.
Summary
Addex Therapeutics reported a significant net loss of CHF 6.7 million for FY2025 and a critically low cash balance of CHF 1.6 million, signaling immediate financial pressure despite pipeline progress.
Key Events · Earnings and Guidance · ADXN
-
Significant Net Loss Reported
The company reported a net loss of CHF 6.7 million for the full year 2025, a sharp decline from a net profit of CHF 7.1 million in 2024.
-
Critically Low Cash Position
Cash and cash equivalents decreased to CHF 1.6 million at December 31, 2025, down from CHF 3.3 million in 2024, indicating a very limited cash runway.
-
Pipeline Progress Highlighted
Addex advanced its GABAB PAM chronic cough candidate in preclinical development and regained rights to its Phase 2 mGlu2 PAM asset, ADX71149.
-
Strategic Collaborations and Investments
The company entered an option agreement with Sinntaxis for mGlu5 NAM in brain injury recovery and made a strategic investment in Stalicla SA, building on the Neurosterix spin-out.
Analysis · ADXN · Life Sciences
Addex Therapeutics reported a substantial net loss of CHF 6.7 million for the full year 2025, a significant reversal from a net profit in the prior year. The company's cash and cash equivalents have fallen to a critical CHF 1.6 million as of December 31, 2025, indicating a very short cash runway. This financial position suggests an urgent need for capital, which could lead to highly dilutive financing events given the company's micro-cap status. While the filing also highlights positive preclinical progress for its GABAB PAM chronic cough candidate and the regaining of rights to a Phase 2 mGlu2 PAM asset, these developments are overshadowed by the severe financial distress. Investors should monitor for potential capital raising activities.
At the time of this filing, ADXN was trading at $7.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.